We are live on ! Find out more
VRAX icon

Virax Biolabs
VRAX

7 hedge funds and large institutions have $990K invested in Virax Biolabs in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

441% more capital invested

Capital invested by funds: $183K → $990K (+$807K)

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

75% more funds holding

Funds holding: 4 → 7 (+3)

0.01% more ownership

Funds ownership: 0% → 0.01% (+0.01%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
7
Holders Change
+3
Holders Change %
+75%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
–
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KI
Kapitalo Investimentos
Brazil
+$167K
2
Legal & General Group
Legal & General Group
United Kingdom
+$146K
3
VF
Virtu Financial
New York
+$68.9K
4
Millennium Management
Millennium Management
New York
+$22K
5
Renaissance Technologies
Renaissance Technologies
New York
+$16.3K

Top Sellers

Rank Fund Capital Flow
1
SSA
Schonfeld Strategic Advisors
New York
-$115K
2
Bank of America
Bank of America
North Carolina
-$28K
3
UBS Group
UBS Group
Switzerland
-$8.53K
4
TRCT
Tower Research Capital (TRC)
New York
-$2K

VRAX Hedge Fund Activity: Q4 2022 in Review

7 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q4 2022, worth a combined $990K — up 441% from $183K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new VRAX positions and 3 closed out — a net gain of 3 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Kapitalo Investimentos, opening a new position worth an estimated $167K. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $115K sold.

  • 7 institutional investors held Virax Biolabs (VRAX) as of Q4 2022, up from 4 in Q3 2022.
  • Funds reported $990K of Virax Biolabs stock for Q4 2022, up 441% quarter-over-quarter.
  • 6 funds opened new Virax Biolabs positions in Q4 2022 and 3 closed out, a net change of +3 holders.
  • The largest Virax Biolabs buyer in Q4 2022 was Kapitalo Investimentos, an estimated $167K added.
  • The largest Virax Biolabs seller in Q4 2022 was Schonfeld Strategic Advisors, an estimated $115K sold.

Based on aggregated 13F filings for Q4 2022.